Last Close
May 15  •  04:00PM ET
1.30
Dollar change
-0.06
Percentage change
-4.41
%
May 14, 8:22 PMINO-3107 BLA advances smoothly toward October 2026 PDUFA, cash runway extended into 2027
Index
-
P/E
-
EPS (ttm)
-1.71
Insider Own
0.50%
Shs Outstand
81.94M
Perf Week
-10.96%
Market Cap
106.52M
Forward P/E
-
EPS next Y
-0.50
Insider Trans
0.00%
Shs Float
81.60M
Perf Month
12.07%
Enterprise Value
77.54M
PEG
-
EPS next Q
-0.25
Inst Own
42.78%
Perf Quarter
-19.25%
Income
-84.93M
P/S
-
EPS this Y
48.37%
Inst Trans
2.28%
Perf Half Y
-33.67%
Sales
0.00M
P/B
14.95
EPS next Y
46.79%
ROA
-123.95%
Perf YTD
-25.29%
Book/sh
0.09
P/C
2.83
EPS next 5Y
-
ROE
-296.36%
52W High
2.98 -56.36%
Perf Year
-33.33%
Cash/sh
0.46
P/FCF
-
EPS past 3/5Y
49.51% 32.44%
ROIC
-716.49%
52W Low
1.03 26.21%
Perf 3Y
-85.89%
Dividend Est.
-
EV/EBITDA
-
Sales past 3/5Y
-81.47% -61.18%
Gross Margin
-
Volatility
11.53% 8.08%
Perf 5Y
-98.35%
Dividend TTM
-
EV/Sales
-
EPS Y/Y TTM
46.40%
Oper. Margin
-
ATR (14)
0.12
Perf 10Y
-98.84%
Dividend Ex-Date
-
Quick Ratio
1.04
Sales Y/Y TTM
-100.00%
Profit Margin
-
RSI (14)
50.89
Dividend Gr. 3/5Y
- -
Current Ratio
1.04
EPS Q/Q
44.16%
SMA20
5.73%
Beta
1.50
Payout
-
Debt/Eq
1.43
Sales Q/Q
-100.00%
SMA50
-4.83%
Rel Volume
0.84
Prev Close
1.36
Employees
112
LT Debt/Eq
0.95
SMA200
-30.03%
Avg Volume
2.31M
Price
1.30
IPO
Dec 08, 1998
Option/Short
Yes / Yes
Trades
Volume
1,947,404
Change
-4.41%
Date Action Analyst Rating Change Price Target Change
Jul-09-25Initiated Piper Sandler Overweight $5
May-14-24Initiated Stephens Overweight $20
Jan-25-24Upgrade Oppenheimer Perform → Outperform $4
Nov-09-22Downgrade Maxim Group Buy → Hold
Nov-01-22Downgrade BofA Securities Neutral → Underperform $2
Jul-19-22Resumed RBC Capital Mkts Sector Perform $5 → $4
May-11-22Downgrade Oppenheimer Outperform → Perform
Jan-21-22Upgrade BofA Securities Underperform → Neutral $8 → $10
Dec-29-21Resumed Jefferies Hold $8 → $6
Sep-10-21Downgrade BofA Securities Neutral → Underperform $9 → $8
May-14-26 08:30AM
01:02AM
May-13-26 04:13PM
04:05PM
May-08-26 08:05AM
04:05PM Loading…
May-01-26 04:05PM
Apr-02-26 08:55AM
Apr-01-26 08:05PM
10:29AM
Mar-30-26 03:47AM
Mar-13-26 08:30AM
Mar-12-26 11:07PM
04:47PM
04:05PM
Mar-09-26 08:05AM
04:05PM Loading…
Mar-05-26 04:05PM
Mar-04-26 09:00AM
08:05AM
Feb-26-26 09:16AM
Feb-25-26 09:00AM
Feb-20-26 04:27AM
Feb-12-26 08:05AM
07:30AM
Dec-30-25 08:10AM
Dec-29-25 08:05AM
Dec-19-25 04:05PM
Nov-18-25 08:05AM
Nov-14-25 12:00PM
Nov-11-25 08:40AM
12:00AM
06:09PM Loading…
Nov-10-25 06:09PM
04:17PM
04:05PM
Nov-03-25 08:05AM
Oct-31-25 04:53PM
Oct-27-25 08:05AM
Oct-23-25 04:05PM
Oct-21-25 08:05AM
Oct-02-25 08:05AM
Sep-25-25 08:05AM
Aug-28-25 10:00AM
Aug-26-25 08:05AM
Aug-25-25 11:04AM
08:05AM
Aug-14-25 12:22PM
Aug-13-25 03:11AM
Aug-12-25 04:20PM
04:05PM
Aug-11-25 06:55PM
09:10AM
08:05AM
Aug-07-25 10:00AM
Aug-05-25 10:00AM
Aug-04-25 04:05PM
Jul-07-25 04:05PM
Jul-03-25 07:30AM
Jul-02-25 04:16PM
Jul-01-25 07:00AM
May-14-25 12:43PM
03:15AM
May-13-25 05:40PM
04:39PM
04:05PM
Apr-30-25 08:05AM
Apr-29-25 08:05AM
Apr-21-25 07:40AM
Apr-09-25 12:00PM
08:05AM
Apr-01-25 09:35AM
Mar-19-25 03:02AM
Mar-18-25 10:15PM
04:05PM
Mar-13-25 06:15PM
Mar-12-25 12:55PM
Feb-12-25 09:55AM
08:00AM
Feb-10-25 08:05AM
Jan-29-25 04:14PM
Jan-09-25 08:04AM
Dec-13-24 07:00AM
Dec-12-24 04:01PM
Dec-03-24 08:00AM
Nov-29-24 04:02PM
Nov-15-24 02:15AM
02:08AM
Nov-14-24 09:15PM
04:27PM
04:05PM
Nov-13-24 08:00AM
Nov-06-24 04:05PM
08:00AM
Oct-21-24 08:00AM
Oct-09-24 05:38AM
Oct-02-24 04:15PM
Oct-01-24 08:00AM
Sep-17-24 04:30PM
Sep-04-24 08:30AM
Aug-09-24 02:30AM
Aug-08-24 04:40PM
04:05PM
Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.
CEODr. Jacqueline E. Shea Ph.D.
Chief Financial OfficerMr. Peter D. Kies
M.B.A.Dr. Michael Sumner B.S.
Chief Scientific Officer & Chairman of the Scientific Advisory BoardDr. Laurent M. Humeau Ph.D.
General CounselMr. Robert L. Crotty J.D.